<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04374175</url>
  </required_header>
  <id_info>
    <org_study_id>20CH035</org_study_id>
    <secondary_id>2020-A00393-36</secondary_id>
    <nct_id>NCT04374175</nct_id>
  </id_info>
  <brief_title>SERum-bank for PANcreatic Cancer</brief_title>
  <acronym>SERPAN</acronym>
  <official_title>SERum-bank for PANcreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is about pancreatic cancer. If the diagnostic cancer is done at an early stage
      (&lt;2cm), the chances of recovery are very good.

      But the main problem is there is not any detections means for this cancer. Sadly, when there
      is a cancer diagnostic , it's already too late in the majority of cases, because the cancer
      is in an advanced case.

      Today, there is no any effective means of detection... Blood markers can be a simple means of
      early detection
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to establish a sero-library in a case-control cohort to assess
      several potentially useful serum biomarkers, such as adiponectin in the early diagnosis of
      pancreatic cancer.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2020</start_date>
  <completion_date type="Anticipated">March 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Serum adiponectin concentration</measure>
    <time_frame>Months : 0</time_frame>
    <description>Measure by blood sample result Serum adiponectin concentration threshold for which the specificity will be 100% for the diagnosis of pancreatic cancer with a sensitivity of 80%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum CA19.9 concentration</measure>
    <time_frame>Months : 0, 3, 6, 9, 12</time_frame>
    <description>Measure by blood sample result Threshold for Comparison of diagnostic performance compared to serum adiponectin concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response and progression rates according to RECIST v1.1</measure>
    <time_frame>Month 12</time_frame>
    <description>Tumor response and progression rates defined according to RECIST v1.1 criteria according to a serum threshold of the prognostic biomarker to be identified by logistic regression analyzes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Months : 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Months : 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum adiponectin concentration</measure>
    <time_frame>Months : 3, 6, 9, 12</time_frame>
    <description>Measure by blood sample result Serum adiponectin concentration to correlate with cancer progression or not.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Adenocarcinoma group</arm_group_label>
    <description>Patients with Adenocarcinoma will be included. They will have blood sample at the inclusion visit and at 3 months, 6 months, 9 months and 12 months after.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Patient with no adenocarcinoma will be included. They will have blood sample at the inclusion visit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <description>Blood sample will be performed</description>
    <arm_group_label>Adenocarcinoma group</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        There are 2 groups: patients with adenocarcinoma (ADENOCARCINOMA GROUP) and without
        (CONTROL GROUP)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        ADENOCARCINOMA GROUP

        Inclusion Criteria:

          -  Documented adenocarcinoma (cytology / anatomopathology), all stages, except if the
             tumor is immediately resectable and does not require preoperative cytological
             evidence. In this case, the inclusion and the first collection of the sero bank is
             done preoperatively. The diagnostic confirmation will therefore be made
             post-operatively at the risk of being excluded in the event of a different diagnosis.

          -  At the start of treatment (before surgery / 1st course of chemotherapy)

          -  Age ≥ 18 years

          -  Patient affiliated or entitled to a social security system

        Exclusion Criteria:

          -  Patient refusal

          -  Acute renal failure

          -  Child-Pugh B or C cirrhosis

          -  Patient under guardianship or curators

          -  Other synchronous cancer or history of cancer &lt;5 years

          -  Language barrier

        CONTROL GROUP

        Inclusion Criteria:

          -  Age ≥ 40 years

          -  Patient affiliated or entitled to a social security system

          -  Digestive endoscopy for any reason other than cancer or chronic inflammatory bowel
             disease

        Exclusion Criteria:

          -  Patient refusal

          -  Acute renal failure

          -  Child-Pugh B or C cirrhosis

          -  Patient under guardianship or curators

          -  Other synchronous cancer or history of cancer &lt;5 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas WILLIET, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Saint-Etienne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicolas WILLIET, MD</last_name>
    <phone>(0)477829029</phone>
    <phone_ext>+33</phone_ext>
    <email>nicolas.williet@chu-st-etienne.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jean-Marc PHELIP, MD-PhD</last_name>
    <phone>( 0)477828320</phone>
    <phone_ext>+33</phone_ext>
    <email>j.marc.phelip@chu-st-etienne.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Cancérologique Lucien Newirth (ICLN)</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lea SABAN-ROCHE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Saint-Etienne</name>
      <address>
        <city>Saint-Étienne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nicolas WILLIET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Marc PHELIP, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 28, 2020</study_first_submitted>
  <study_first_submitted_qc>May 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2020</study_first_posted>
  <last_update_submitted>May 14, 2020</last_update_submitted>
  <last_update_submitted_qc>May 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adenocarcinoma</keyword>
  <keyword>Pancreatic cancer</keyword>
  <keyword>Adiponectin</keyword>
  <keyword>Blood sample</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

